短期局部使用米诺西迪尔与急性中央血清性胆色素变异相关:一个病例报告
Jacob Brucker1, Brian Mihok1, Jeffrey Bloom2
1Ophthalmology, Kettering Health, Dayton, OH, USA.
Case reports in ophthalmology
|December 1, 2025
概括
局部使用用于脱发的米诺西迪尔,即使在使用一周后也可能导致中央血清性胆色素变异 (CSCR). 这种情况在患者停止药物治疗和观察后得到解决.
科学领域:
- 眼科医生 眼科 眼科
- 皮肤病学 皮肤病学
背景情况:
- 局部用米诺克西迪尔被FDA批准用于治疗模式脱发.
- 以前的报道将长期使用米诺西迪尔与中央血清性胆色素变异症 (CSCR) 联系起来.
研究的目的:
- 报告一个可能由短期局部使用米诺克西迪尔引起的CSCR病例.
主要方法:
- 一个34岁的男性的案例研究,他患有新出现的视力障碍.
- 进行了眼科检查和光学连贯性断层扫描 (OCT).
- 局部用米诺克西迪尔的治疗被停止,并对患者进行观察.
主要成果:
- 患者出现了亚急性中央视力损失和一只眼睛的闪.
- 眼科发现与CSCR一致.
- 在停止使用米诺克西迪尔后6周内,CSCR完全消失.
结论:
- 短期局部使用米诺克西迪尔,只需一周,可能会诱导CSCR.
- 停止使用米诺克西迪尔和观察是米诺克西迪尔诱导的CSCR的有效管理策略.
更多相关视频
07:36Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
Published on: July 3, 2025
587
04:00Author Spotlight: Establishing a Practical and Cost-Effective Protocol for Corneal Sensitivity Testing in Clinical Settings
Published on: August 2, 2024
3.1K
相关概念视频
Angle Closure Glaucoma: Treatment
1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K
Open Angle Glaucoma: Treatment
934
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
934
